» Articles » PMID: 28743793

Animal Models of MEN1

Overview
Specialties Endocrinology
Oncology
Date 2017 Jul 27
PMID 28743793
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Animal models of cancer have been instrumental in advancing our understanding of the biology of tumor initiation and progression, in studying gene function and in performing preclinical studies aimed at testing novel therapies. Several animal models of the MEN1 syndrome have been generated in different organisms by introducing loss-of-function mutations in the orthologues of the human gene. In this review, we will discuss MEN1 and MEN1-like models in Drosophila, mice and rats. These model systems with their specific advantages and limitations have contributed to elucidate the function of Menin in tumorigenesis, which turned out to be remarkably conserved from flies to mammals, as well as the biology of the disease. Mouse models of MEN1 closely resemble the human disease in terms of tumor spectrum and associated hormonal changes, although individual tumor frequencies are variable. Rats affected by the MENX (MEN1-like) syndrome share some features with MEN1 patients albeit they bear a germline mutation in (p27) and not in Both -knockout mice and MENX rats have been exploited for therapy-response studies testing novel drugs for efficacy against neuroendocrine tumors (NETs) and have provided promising leads for novel therapies. In addition to presenting well-established models of MEN1, we also discuss potential models which, if implemented, might broaden even further our knowledge of neuroendocrine tumorigenesis. In the future, patient-derived xenografts in zebrafish or mice might allow us to expand the tool-box currently available for preclinical studies of MEN1-associated tumors.

Citing Articles

Whole-Exome Screening and Analysis of Signaling Pathways in Multiple Endocrine Neoplasia Type 1 Patients with Different Outcomes: Insights into Cellular Mechanisms and Possible Functional Implications.

Skalniak A, Trofimiuk-Muldner M, Surmiak M, Toton-Zuranska J, Jabrocka-Hybel A, Hubalewska-Dydejczyk A Int J Mol Sci. 2024; 25(2).

PMID: 38256138 PMC: 10816043. DOI: 10.3390/ijms25021065.


Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects.

Gulde S, Foscarini A, April-Monn S, Genio E, Marangelo A, Satam S Cancers (Basel). 2022; 14(22).

PMID: 36428573 PMC: 9688197. DOI: 10.3390/cancers14225481.


Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin.

Cheng Z, Guo D, Ruzi A, Pan T, You K, Chen Y Cells. 2022; 11(15).

PMID: 35954231 PMC: 9368616. DOI: 10.3390/cells11152387.


Gastrin: From Physiology to Gastrointestinal Malignancies.

Duan S, Rico K, Merchant J Function (Oxf). 2022; 3(1):zqab062.

PMID: 35330921 PMC: 8788842. DOI: 10.1093/function/zqab062.


A Novel Isogenic Human Cell-Based System for MEN1 Syndrome Generated by CRISPR/Cas9 Genome Editing.

Klementieva N, Goliusova D, Krupinova J, Yanvarev V, Panova A, Mokrysheva N Int J Mol Sci. 2021; 22(21).

PMID: 34769484 PMC: 8584395. DOI: 10.3390/ijms222112054.